Alterins Produced by Oyster-Associated Pseudoalteromonas Are Antibacterial Cyclolipopeptides with LPS-Binding Activity

Mar Drugs. 2020 Dec 10;18(12):630. doi: 10.3390/md18120630.

Abstract

Discovery after discovery, host-associated microbiota reveal a growing list of positive effects on host homeostasis by contributing to host nutrition, improving hosts' immune systems and protecting hosts against pathogens. In that context, a collection of oyster associated bacteria producing antibacterial compounds have been established to evaluate their role in non-host-derived immunity. Here, we described alterins; potent anti-Gram negative compounds produced by Pseudoalteromonas hCg-6 and hCg-42 isolated from different healthy oyster hemolymph. The strains hCg-6 and hCg-42 produce a set of at least seven antibacterial compounds, ranging from 926 to 982 Da structurally characterized as cyclolipopeptides (CLPs). Alterins share the same cationic heptapeptidic cycle connected via an amido bond to different hydrophobic hydrocarbon tails. Their MICs disclosed a potent antibacterial activity directed against Gram-negative bacteria including oyster and human pathogens that may confer a beneficial defense mechanism to the host but also represents an untapped source of new antibiotics. The alterins' mechanisms of action have been deciphered: after binding to lipopolysaccharides (LPS), alterins provoke a membrane depolarization and permeabilization leading to bacterial lysis. As hCg-6 and hCg-42 produced a set of natural derivatives, the structure/activity relationship linked to the carbon tail is clarified. We showed that the hydrocarbon tail determines the LPS-binding properties of alterins and consequently their antibacterial activities. Its length and saturation seem to play a major role in this interaction.

Keywords: Pseudoalteromonas; alterin; antibiotic; cyclolipopeptides.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / isolation & purification
  • Anti-Bacterial Agents / metabolism
  • Anti-Bacterial Agents / pharmacology*
  • Antimicrobial Cationic Peptides / isolation & purification
  • Antimicrobial Cationic Peptides / metabolism
  • Antimicrobial Cationic Peptides / pharmacology*
  • Gram-Negative Bacteria / drug effects*
  • Gram-Negative Bacteria / growth & development
  • Hemolymph / microbiology
  • Host-Pathogen Interactions
  • Lipopeptides / isolation & purification
  • Lipopeptides / metabolism
  • Lipopeptides / pharmacology*
  • Lipopolysaccharides / metabolism*
  • Microbial Sensitivity Tests
  • Ostreidae / microbiology*
  • Peptides, Cyclic / isolation & purification
  • Peptides, Cyclic / metabolism
  • Peptides, Cyclic / pharmacology*
  • Pseudoalteromonas / metabolism*
  • Structure-Activity Relationship

Substances

  • Anti-Bacterial Agents
  • Antimicrobial Cationic Peptides
  • Lipopeptides
  • Lipopolysaccharides
  • Peptides, Cyclic
  • lipopolysaccharide, Escherichia coli O111 B4